Back to results

CompletedN/A

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer

NCT02064829

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Sorrento investigational site

Fayetteville, Arkansas, United States

+19 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2014-03
Enrollment: 111 participants
Sponsor: Sorrento Therapeutics, Inc.
Purpose: treatment

Locations (20)

Sorrento investigational siteFayetteville, Arkansas, United States
Sorrento investigational siteChattanooga, Tennessee, United States
Sorrento investigational siteMemphis, Tennessee, United States
Sorrento investigational siteFlower Mound, Texas, United States
Sorrento investigational siteBatumi, Georgia
Sorrento investigational siteTbilisi, Georgia
Sorrento investigational siteChisinau, Moldova
Sorrento investigational siteBucharest, Romania
Sorrento investigational siteBelgrade, Serbia
Sorrento investigational siteKamenitz, Serbia
Sorrento investigational siteKragujevac, Serbia
Sorrento investigational siteZrenjanin, Serbia
Sorrento investigational siteSingapore, Singapore
Sorrento investigational siteCherkasy, Ukraine
Sorrento investigational siteDnipropetrovsk, Ukraine
Sorrento investigational siteKharkiv, Ukraine
Sorrento investigational siteKyiv, Ukraine
Sorrento investigational siteLviv, Ukraine
Sorrento investigational siteSumy, Ukraine
Sorrento investigational siteVinnytsia, Ukraine

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer — TrialFind